Publications by authors named "Gretchen D Ball"
Background: Psoriatic arthritis (PsA) is undiagnosed in up to 41% of cases, risking irreversible joint damage if untreated. This quality improvement initiative facilitates PsA screening, assessment, and rheumatology referral to improve patient outcomes.
Methods: Our clinical framework integrated the Psoriasis Epidemiology Screening Tool (PEST) and the 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) into the electronic medical record system in 26 dermatology clinics.
Background: Although cases of pyoderma gangrenosum (PG) during pregnancy have been reported, comprehensive data are limited. This review aims to (1) analyze the demographic and clinical characteristics of PG in pregnant and postpartum patients, (2) assess the frequency and effectiveness of treatments, and (3) explore the maternal and fetal implications of PG.
Methods: A systematic review was conducted following PRISMA guidelines, with searches in PubMed, Embase, and Web of Science up to September 27, 2023.
Article Synopsis
- * A case was reported of a 52-year-old woman with extensive LP covering 80% of her body, which improved significantly to 20% after two months of treatment with the JAK inhibitor deucravacitinib.
- * Deucravacitinib uniquely targets a specific part of the immune response (tyrosine kinase 2), providing a potentially safer and more effective long-term treatment alternative for chronic skin conditions like LP.
Diagnostic Delay of Psoriatic Arthritis of More Than Six Months Contributes to Poor Patient-Reported Outcome Measures in Depression, Social Ability, and Disease Impact: A Cross-sectional Study.
J Clin Aesthet Dermatol
October 2024
Objective: We sought to correlate the time lag between psoriatic arthritis (PsA) symptom onset and diagnosis to the likelihood and severity of depression, social impairment, and disease impact on quality of life.
Methods: This cross-sectional study conducted by the National Psoriasis Foundation (NPF) surveyed individuals with PsA using patient-reported outcome measures.
Results: The analysis cohort comprised 2,196 patients with PsA.
Article Synopsis
- - Psoriasis (PsO) is categorized as mild, moderate, or severe primarily based on body surface area (BSA), and mild cases typically receive topical treatments; however, there's debate over when to use biologics as first-line options even for mild cases.
- - At the GRAPPA 2023 meeting, proponents of biologics highlighted cases like psoriatic arthritis (PsA) and significant symptoms on sensitive areas (such as the scalp or genitals) as reasons to consider biologic therapy for mild PsO.
- - Critics argue that true mild PsO shouldn't include patients with PsA or major quality of life issues, advocating instead for topical treatments that are safer and more cost-effective, especially with newer options
The nonprofit organization International Dermatology Outcome Measures (IDEOM) is committed to improving the implementation of patient-centered outcome measures in dermatologic disease. At a conference adjacent to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting, the IDEOM Psoriatic Disease Workgroup presented updates on recent efforts in outcome measure advancement. Dr.
View Article and Find Full Text PDF